Lativia -
Kilatvia -
Zāļu valsts aģentūra
conoxia 100% medicīniskā gāze, kriogēna
linde gas, sweden - skābeklis - medicīniskā gāze, kriogēna - 100%
Lativia -
Kilatvia -
Zāļu valsts aģentūra
conoxia 100% medicīniskā gāze, saspiesta
linde gas, sweden - skābeklis - medicīniskā gāze, saspiesta - 100%
Umoja wa Ulaya -
Kilatvia -
EMA (European Medicines Agency)
tecvayli
janssen-cilag international n.v. - teclistamab - multiple mieloma - antineoplastiski līdzekļi - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
Lativia -
Kilatvia -
Pārtikas un veterinārais dienests, Zemkopības ministrija
bronchos pastilas ar medu (paziņots 2013.) pastila
ražots Šveicē pēc uab „acorus calamus” pasūtījuma - pastila
Lativia -
Kilatvia -
Pārtikas un veterinārais dienests, Zemkopības ministrija
bronchos pastilas ar salviju (paziņots 2013.) pastila
ražots Šveicē pēc uab „acorus calamus” pasūtījuma - pastila
Umoja wa Ulaya -
Kilatvia -
EMA (European Medicines Agency)
lunsumio
roche registration gmbh - mosunetuzumab - limfoma, folikulāra - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
Umoja wa Ulaya -
Kilatvia -
EMA (European Medicines Agency)
carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - multiple mieloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.